Have a feature idea you'd love to see implemented?
Let us know!
LENZ LENZ Therapeutics Inc.
Price (delayed)
$34.32
Market cap
$943.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.95
Enterprise value
$903.62M
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process
Highlights
LENZ Therapeutics's debt has shrunk by 98% YoY and by 9% QoQ
The EPS has soared by 81% YoY and by 65% from the previous quarter
Key stats
What are the main financial stats of LENZ
Market
Valuations
Earnings
Shares outstanding
27.5M
Market cap
$943.83M
Enterprise value
$903.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$60.04M
EBITDA
-$59.43M
Free cash flow
-$95.88M
Per share
Balance sheet
Liquidity
EPS
-$4.95
Free cash flow per share
-$3.53
Book value per share
$7.83
Revenue per share
$0
TBVPS
$8.24
Total assets
$224.01M
Total liabilities
$8.73M
Debt
$953,000
Equity
$215.28M
Working capital
$212.99M
Debt to equity
0
Current ratio
28.63
Quick ratio
28.17
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.6%
Return on equity
-46.8%
Return on invested capital
-79.5%
Return on capital employed
-27.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LENZ stock price
How has the LENZ Therapeutics stock price performed over time
Intraday
1.21%
1 week
1.15%
1 month
26.22%
1 year
111.33%
YTD
87.13%
QTD
44.57%
Financial performance
How have LENZ Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.94M
Net income
-$60.04M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 15% YoY and by 13% QoQ
LENZ's operating income is up by 9% since the previous quarter and by 7% year-on-year
Growth
What is LENZ Therapeutics's growth rate over time
Valuation
What is LENZ Therapeutics stock price valuation
P/E
N/A
P/B
4.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 81% YoY and by 65% from the previous quarter
The equity is up by 12% since the previous quarter and by 6% year-on-year
Efficiency
How efficient is LENZ Therapeutics business performance
The return on invested capital has dropped by 128% year-on-year but it has increased by 28% since the previous quarter
LENZ Therapeutics's ROE has plunged by 65% YoY but it has increased by 14% from the previous quarter
LENZ's return on assets is down by 41% year-on-year but it is up by 7% since the previous quarter
Dividends
What is LENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LENZ.
Financial health
How did LENZ Therapeutics financials performed over time
LENZ's total liabilities has dropped by 86% year-on-year and by 10% since the previous quarter
LENZ Therapeutics's current ratio has soared by 50% YoY and by 23% from the previous quarter
LENZ Therapeutics's debt is 100% lower than its equity
LENZ Therapeutics's debt to equity has plunged by 100% from the previous quarter and by 100% YoY
LENZ Therapeutics's debt has shrunk by 98% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.